Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. - Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE (Expert opinion on biological therapy, 2010)